Pregled bibliografske jedinice broj: 538011
The value of negative F-18-FDG-PET in patients with Hodgkin’s disease and residual mass after therapy
The value of negative F-18-FDG-PET in patients with Hodgkin’s disease and residual mass after therapy // Nuklearmedizin
Stuttgart: Schattauer, 2011. str. A 147-A 147 (predavanje, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 538011 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
The value of negative F-18-FDG-PET in patients with Hodgkin’s disease and residual mass after therapy
Autori
Huić, Dražen ; Andrea, Mutvar ; Kinda-Bašić, Sandra ; Aurer, Igor ; Ciglar, Martina ; Grošev, Darko ; Radman, Ivo ; Labar, Boris ; Dodig, Damir
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Nuklearmedizin
/ - Stuttgart : Schattauer, 2011, A 147-A 147
Skup
7th International Congress of the Croatian Society of Nuclear Medicine
Mjesto i datum
Opatija, Hrvatska, 15.05.2011. - 18.05.2011
Vrsta sudjelovanja
Predavanje
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
FDG-PET; Hodgkin's disease; residual mass; therapy
Sažetak
THE VALUE OF NEGATIVE F-18-FDG-PET IN PATIENTS WITH HODGKIN'S DISEASE AND A RESIDUAL MASS AFTER THERAPY Dražen Huić, Andrea Mutvar, Sandra Kinda-Bašić, Igor Aurer, Martina Ciglar, Darko Grošev, Ivo Radman, Boris Labar, Damir Dodig Department of Nuclear Medicine and Radiation Protection, Department of Internal Medicine, Division of Hematology, Zagreb University Hospital Centre, Zagreb, Croatia Aim: To asses the negative predictive value (NPV) of FDG-PET performed with triple-head coincidence gamma camera after first-line therapy or salvage therapy in patients with Hodgkin’s disease (HD) compared by long-term follow-up as a reference standard. Design and Setting: This single centre retrospective diagnostic test study was done in University Hospital Centre between June 2001 and February 2008. Participants: The charts of 131 consecutive patients with Hodgkin’s disease were reviewed. Seventy-three consecutive PET-negative patients (median age 28 years ; range 12-80 years) with primary or recurrent biopsy confirmed lymphoma after first-line therapy or salvage therapy were followed-up at least 12 months (median 23 months ; range 12-69 months). All already performed 18F-FDG PET scans (using hybrid PET camera with triple head coincidence imaging capability within a few months after completion of therapy) were again visually interpreted by two board-certified nuclear medicine physicians who were blinded to any clinical or CT data. Main outcome measure: The negative predictive value of FDG-PET performed with triple-head coincidence gamma camera (Index test) was compared with long-term follow-up as a reference standard. Results: Out of 131 patients 73 turned-out to be PET-negative. Of those 73 PET-negative patients 61 patients have been scanned after first-line chemotherapy/radiotherapy, and only 3 (4.9%) of them relapsed in a follow-up (negative predictive value 95%). Twelve patients with resistant disease have been scanned after repeated therapy, and 4 (25%) of them relapsed in a follow-up period (negative predictive value 66%). Conclusions: This methodology with triple-head coincidence gamma camera has high negative predictive value in patients with Hodgkin's disease.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
108-1081872-1908 - Dijagnostika i liječenje limfoma (Aurer, Igor, MZOS ) ( CroRIS)
108-1081872-2062 - Uloga pozitronske emisijske tomografije (PET) u bolesnika sa zloćudnim tumorima (Huić, Dražen, MZOS ) ( CroRIS)
214-0362214-2055 - Kvantifikacija i parametrizacija akumulacije FDG-a pomoću PET-a (Lončarić, Srećko, MZOS ) ( CroRIS)
Ustanove:
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb
Profili:
Boris Labar
(autor)
Damir Dodig
(autor)
Igor Aurer
(autor)
Dražen Huić
(autor)
Darko Grošev
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE